Consolidation ALK Tyrosine Kinase Inhibitors versus Durvalumab or Observation After Chemoradiation in Unresectable Stage III ALK+ Non-Small Cell Lung Cancer

By sjmartinez • September 12, 2024

Nassar AH, Jayakrishnan R, Feng J, Shepherd F, Adib E, Cheung JM, Lin JJ, Liu Y, Lin SH, Parikh K, Sridhar A, Shakya P, Dilling TJ, Kaldas D, Gray JE, Lobachov A, Bar J, Luders H, Grohe C, Gupta S, Leal T, Fitzgerald B, Crowley F, Fujiwara Y, Marron TU, Wilgucki M, Reuss J, Chen L, Sankar K, Aredo JV, Neal JW, Wakelee HA, Thummalapalli R, Yu H, Whitaker R, Velazquez A, Ragavan M, Cortellini A, Kwiatkowski DJ, Naqash AR, Goldberg SB, Kim SY. Consolidation ALK Tyrosine Kinase Inhibitors versus Durvalumab or Observation After Chemoradiation in Unresectable Stage III ALK+ Non-Small Cell Lung Cancer. J Thorac Oncol. 2024 Sep 9:S1556-0864(24)02265-2. doi: 10.1016/j.jtho.2024.09.1379. Epub ahead of print. PMID: 39260522.

Tags: Cedars Sinai DoM, Hematology/Oncology, Publications

Psychosocial and clinical characteristics in Takotsubo syndrome

Obrutu O, Cui Y, Maughan J, Marano P, Wei J, Gulati M, Lauzon M, Herscovici R, Shufelt C, Rojas N, Tjoe B, Rutledge T, Bairey[...]

Loss of TRIM21 drives UVB-induced systemic inflammation by regulating DNA-sensing pathways

Tumurkhuu G, Perri G, Moore R, Huo L, Kumar AN, Ainsworth R, Oliver T, de Los Santos G, Gibb D, Carriere J, Yu JM, Abuav[...]

Reply to the letter to the editor on “Re: “Sex Disparities in Alcohol-Associated Liver Disease and Subtype Differences in Alcohol-attributable Cancers in the United States”

Danpanichkul P, Diaz LA, Arab JP, Singal AG, Yang JD. Reply to the letter to the editor on "Re: "Sex Disparities in Alcohol-Associated Liver Disease[...]